Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance

Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance High plasminogen activator inhibitor 1 (PAI‐1) levels are associated with an increased cardiovascular risk of atherothrombosis. Furthermore, increased plasma PAI‐1 levels are associated with dyslipidemia, hyperinsulinemia and hypertension. This association between PAI‐1 and metabolic components of the Metabolic Syndrome could explain the predisposition of insulin resistant patients to atherothrombosis. Recent studies have suggested that visceral adipose tissue might be the link between elevated plasma PAI‐1 and insulin resistance in the Metabolic Syndrome. Indeed, visceral adipose tissue was proposed as a potentially important source of PAI‐1 in humans. However, in light of recent studies, visceral adipose tissue appears to be involved in the increase of plasma PAI‐1 via the metabolic disorders usually associated with central obesity, rather than directly. High plasma PAI‐1 levels are undoubtedly related to insulin resistance, and the mechanisms which could explain such an increase in the Metabolic Syndrome appear to be multi‐factorial and remain to be elucidated. These mechanisms may involve several metabolic disorders such as hyperinsulinemia, dyslipidemia, impaired glucose tolerance and hypertension, which would favor PAI‐1 synthesis and release from different cell types. Copyright © 2000 John Wiley & Sons, Ltd. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetes/Metabolism: Research and Reviews Wiley

Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance

Download PDF
10 pages

Loading next page...
 
/lp/wiley/relationship-between-plasma-plasminogen-activator-inhibitor-1-and-rYNd0pwHq5

References (152)

Publisher
Wiley
Copyright
Copyright © 2000 Wiley Subscription Services, Inc., A Wiley Company
ISSN
1520-7552
eISSN
1520-7560
DOI
10.1002/1520-7560(200005/06)16:3<192::AID-DMRR114>3.0.CO;2-G
Publisher site
See Article on Publisher Site

Abstract

High plasminogen activator inhibitor 1 (PAI‐1) levels are associated with an increased cardiovascular risk of atherothrombosis. Furthermore, increased plasma PAI‐1 levels are associated with dyslipidemia, hyperinsulinemia and hypertension. This association between PAI‐1 and metabolic components of the Metabolic Syndrome could explain the predisposition of insulin resistant patients to atherothrombosis. Recent studies have suggested that visceral adipose tissue might be the link between elevated plasma PAI‐1 and insulin resistance in the Metabolic Syndrome. Indeed, visceral adipose tissue was proposed as a potentially important source of PAI‐1 in humans. However, in light of recent studies, visceral adipose tissue appears to be involved in the increase of plasma PAI‐1 via the metabolic disorders usually associated with central obesity, rather than directly. High plasma PAI‐1 levels are undoubtedly related to insulin resistance, and the mechanisms which could explain such an increase in the Metabolic Syndrome appear to be multi‐factorial and remain to be elucidated. These mechanisms may involve several metabolic disorders such as hyperinsulinemia, dyslipidemia, impaired glucose tolerance and hypertension, which would favor PAI‐1 synthesis and release from different cell types. Copyright © 2000 John Wiley & Sons, Ltd.

Journal

Diabetes/Metabolism: Research and Reviews – Wiley

Published: May 1, 2000

Keywords: ; ; ; ; ;

There are no references for this article.